<div style="text-align:justify;"> Advances in Lung Cancer (ALC) is a peer-reviewed, open access journal published quarterly. The goal of this journal is to provide a platform for doctors and academicians all over the world to promote, share, and discuss various new issues and developments in all aspects of basic and clinical lung cancer research. </div> <div style="text-align:justify;"> <br /> </div> <p style="text-align:justify;"> All manuscripts must be prepared in English and are subject to a rigorous peer-review process. Generally, accepted papers will appear online within 3 weeks followed by printed hard copy. The areas covered by Advances in Lung Cancer (ALC) include but are not limited to the following fields: </p> <p> <br /> </p> Fri, 14 Jul 2017 10:39:09 GMT en 30 service@scirp.org 2017-06-22 <div style=line-height:22px; width=100%><b>Patient-Reported Outcomes of Chemotherapy Involving Non-Small Cell Lung Cancer: Evaluation by Questionnaires of Quality of Life Regarding Anti-Aging and Anti-Cancer Drugs</b><br>Patient-Reported Outcome, Chemotherapy, Quality of Life, Non-Small Cell Lung Cancer<br><a href=http://www.scirp.org/journal/PaperInformation.aspx?paperID=77085 target=_blank>Paper Information</a> Full Paper: <a href=http://www.scirp.org/journal/PaperDownload.aspx?FileName=ALC_2017062215501230.pdf&paperID=77085>PDF</a> (Size:445KB)<br>DOI: 10.4236/alc.2017.62002<br><br></div> service@scirp.org 2017-03-22 <div style=line-height:22px; width=100%><b>Granulocyte Colony-Stimulating Factor Enhances the Anticancer Effects of Cisplatin against Lung Cancer by Promoting Angiogenesis</b><br>Granulocyte Colony-Stimulating Factor, Lung Cancer, G-CSF Receptor, Angiogenesis, Anticancer Agent, Cisplatin, TNF-Alpha, IL-12<br><a href=http://www.scirp.org/journal/PaperInformation.aspx?paperID=77081 target=_blank>Paper Information</a> Full Paper: <a href=http://www.scirp.org/journal/PaperDownload.aspx?FileName=ALC_2017062215401849.pdf&paperID=77081>PDF</a> (Size:582KB)<br>DOI: 10.4236/alc.2017.61001<br><br></div>